KRAS and non-small cell lung carcinoma: Thus, successful targeting KRAS G12C in NSCLC employing sotorasib (AMG 510) and adagrasib (MRTX849) has a minor impact for PDAC that exhibit G12C mutations in 1–2% of cases [17–19].